Investors

Why Invest in Lxbio?

Inno­va­tion | Glob­al impact
Expan­sive | Mar­ket poten­tial
Sus­tain­able Growth | For the long term
Con­tact Us

Our plat­form tech­nolo­gies are built for expan­sion, enabling rapid deploy­ment across mul­ti­ple high-val­ue mar­kets and unlock­ing broad oppor­tu­ni­ties for licens­ing, part­ner­ships, and scal­able growth

Bacteriophage

One Platform. Multiple Markets

Antimi­cro­bial Resis­tance (AMR) is a grow­ing glob­al health cri­sis as con­ven­tion­al antibi­otics increas­ing­ly fail against mul­tidrug-resis­tant bac­te­ria, cre­at­ing major clin­i­cal and eco­nom­ic chal­lenges.

Bac­te­rio­phages offer a pow­er­ful alter­na­tive. These nat­ur­al virus­es selec­tive­ly infect and destroy bac­te­ria, pro­vid­ing tar­get­ed antimi­cro­bial activ­i­ty with strong safe­ty pro­files. Phage-based ther­a­peu­tics rep­re­sent a promis­ing next-gen­er­a­tion solu­tion to com­bat AMR. 

Bac­te­rio­phages are a pow­er­ful bio­log­i­cal plat­form
with appli­ca­tions across mul­ti­ple high-val­ue mar­kets.

image5

Animal Health

Agriculture & Animal Prodution

Militar Aplications

Potencial applications

Phage-based Delivery Systems

One Platform. Multiple drugs aplications

Our bac­te­rio­phage pre­ci­sion plat­form har­ness­es the nat­ur­al tar­get­ing abil­i­ty of phages to deliv­er ther­a­peu­tic pay­loads direct­ly to bio­log­i­cal tar­gets.

Engi­neered to car­ry small-mol­e­cule drugs such as antibi­otics or bio­log­ics includ­ing anti­bod­ies, the plat­form enables local­ized and pre­cise drug deliv­ery.

This approach may improves effi­ca­cy while reduc­ing sys­temic tox­i­c­i­ty and dos­ing require­ments. The mod­u­lar design sup­ports mul­ti­ple ther­a­peu­tic pay­loads and indi­ca­tions.

A scal­able tech­nol­o­gy with strong com­mer­cial poten­tial across infec­tious dis­eases, micro­bio­me mod­u­la­tion, and tar­get­ed bio­log­ic deliv­ery mar­kets

CAR‑T

Next-generation CAR‑T therapies with targeted precision

CAR-T CELL

Our Dual Viral Plat­form Archi­tec­ture com­bines inte­gra­tive and non-inte­gra­tive vec­tor sys­tems to enable pre­cise con­trol of CAR expres­sion, improv­ing safe­ty, dura­bil­i­ty, and ther­a­peu­tic per­for­mance.

Through advanced vec­tor and con­struct design, the plat­form sup­ports the devel­op­ment of next-gen­er­a­tion CAR ther­a­pies with poten­tial in the treat­ment of sol­id tumors.

A dual viral plat­form enabling pre­cise CAR expres­sion to improve safe­ty and dura­bil­i­ty in next-gen­er­a­tion thera­pies for sol­id tumors.

Advanced Antibodies Research

Discovery and Engineering the Future of Antibody Therapeutics

Advanced anti­body engi­neer­ing is enabling the devel­op­ment of next-gen­er­a­tion bio­phar­ma­ceu­ti­cal ther­a­peu­tics with high speci­fici­ty and pre­ci­sion. Our research focus­es on the dis­cov­ery and devel­op­ment of engi­neered anti­body frag­ments, includ­ing Fab, scFv (sin­gle-chain vari­able frag­ments), and nanobod­ies.

These anti­body-derived mol­e­cules are small­er and more ver­sa­tile than con­ven­tion­al anti­bod­ies, offer­ing improved tis­sue pen­e­tra­tion, tar­get­ing pre­ci­sion, and design flex­i­bil­i­ty. Their mod­u­lar struc­ture also enables inte­gra­tion into advanced ther­a­peu­tic for­mats such as tar­get­ed drug deliv­ery sys­tems and mul­ti­func­tion­al bio­log­ics. Our anti­body engi­neer­ing plat­form sup­ports the devel­op­ment of inno­v­a­tive bio­log­ic ther­a­pies address­ing crit­i­cal unmet needs in oncol­o­gy, oph­thal­mol­o­gy, der­ma­tol­ogy, and oth­er com­plex dis­eases.

A dual viral plat­form enabling pre­cise CAR expres­sion to improve safe­ty and dura­bil­i­ty in next-gen­er­a­tion ther­a­pies for sol­id tumors

Pipeline Clínico
Prod­uctIndi­ca­tionProd­uctProof
of con­cept		Pre­clin­i­cal
devel­op­ment		Clin­i­cal tri­als
Phase 1		Clin­i­cal tri­als
Phase 2		Clin­i­cal tri­als
Phase 3
Top­i­cal Bac­te­rio­phages
cock­tail Dia­betes		Dia­bet­ic foot
infec­tion		TP-102
COMPLETED
IN
DEVELOPMENT
Anti-VEGF encap­su­lat­ed in
nanopar­ti­cles eye­drops		Mac­u­lar Degen­er­a­tion
& Dia­bet­ic retinopa­thy		LXOP02
Eye­drops gel
Bac­te­rio­phages		Ble­phar­i­tis & Ocu­lar infec­tionLXOP01
Phage-based
Deliv­ery Sys­tems		Sev­er­al ther­a­peu­ti­cal
tar­gets		LXON01
Top­i­cal Bac­te­rio­phages
plus cal­cineurin inhibitor		Atopic
Der­mati­tis		LXDE01

Insights from our partners on the value of Lxbio

Message from Lxbio Founder & Chairman

In just four years, LxBio Phar­ma­ceu­ti­cals has estab­lished itself as a com­pelling force in next-gen­er­a­tion biotech­nol­o­gy, attract­ing strong inter­na­tion­al part­ner­ships and investors who recog­nise the trans­for­ma­tive poten­tial of our sci­en­tif­ic plat­forms.

To date, LxBio has raised over €20 mil­lion and achieved an inde­pen­dent val­u­a­tion exceed­ing €100 mil­lion, a mile­stone that reflects sus­tained con­fi­dence in our sci­ence, our lead­er­ship, and our abil­i­ty to exe­cute.

We remain firm­ly com­mit­ted to advanc­ing inno­v­a­tive ther­a­peu­tics and build­ing LxBio into a glob­al­ly sig­nif­i­cant biotech com­pa­ny, deliv­er­ing break­through solu­tions for patients world­wide.

Jorge Brandão

Message from a Partner Investor

LxBio is build­ing some­thing Europe urgent­ly needs: a cap­i­tal-effi­cient plat­form at the fron­tier of advanced ther­a­peu­tics. From CAR‑T and mon­o­clon­al anti­bod­ies to phage tech­nol­o­gy, one of the most promis­ing respons­es to the glob­al antimi­cro­bial resis­tance cri­sis, the breadth and ambi­tion of the com­pa­ny are excep­tion­al. We’re proud to have been the first insti­tu­tion­al investor to back this vision.

Explor­er Invest­ments

Message from a Partner Investor

At Fund­Box SGOIC, we strong­ly believe in Lxbio Phar­ma­ceu­ti­cals’ vision and the trans­for­ma­tive poten­tial of its sci­en­tif­ic plat­forms. Through our Inno­va­tion, Research & Cre­ativ­i­ty (IRC) and Por­tu­gal Panora­ma funds, we invest­ed €3 mil­lion as a reflec­tion of our con­fi­dence in the company’s inno­va­tion, the ded­i­ca­tion of its team, and the mean­ing­ful impact its ther­a­pies may have on mil­lions of lives world­wide.

We are proud to sup­port Lxbio’s mis­sion to address antimi­cro­bial resis­tance and oth­er crit­i­cal unmet med­ical needs.

Fund­Box

Message from João Gonçalves, PhD

Fac­ul­ty of Phar­ma­cy, Lis­bon

With more than 180 sci­en­tif­ic pub­li­ca­tions João Gonçalves is an inter­na­tion­al rec­og­nized sci­en­tist in anti­bod­ies, virus, CAR‑T and Syn­thet­ic-biol­o­gy.

“As a researcher work­ing at the inter­face of CAR‑T tech­nolo­gies, I see enor­mous poten­tial in the inno­v­a­tive approach devel­oped by Lxbio. Their CART plat­form explores anti­body-tar­get­ed capa­ble of deliv­er­ing genet­ic pro­grams direct­ly in vivo with high speci­fici­ty and safe­ty.”

João Gonçalves, PhD

Message from Luís Melo, PhD

Fac­ul­ty of Phar­ma­cy, Coim­bra

With more than 65 sci­en­tif­ic pub­li­ca­tions Luís Melo is an inter­na­tion­al rec­og­nized sci­en­tist in Bio­med­ical Engi­neer­ing and is at the fore­front of Phages R&D.

“Bac­te­rio­phages are pow­er­ful and high­ly selec­tive bio­log­i­cal tools with strong poten­tial to address antimi­cro­bial resis­tance. The work devel­oped by Lxbio demon­strates how advanced phage tech­nolo­gies can trans­late this nat­ur­al pre­ci­sion into inno­v­a­tive clin­i­cal appli­ca­tions, open­ing new paths for tar­get­ed antimi­cro­bial ther­a­pies.”

Luís Melo, PhD

Message from José António Dias, MD

Oph­thal­mol­o­gist

With more than 100 sci­en­tif­ic pub­li­ca­tions and over 180 inter­na­tion­al pre­sen­ta­tions, Dr. José is a rec­og­nized ref­er­ence in oph­thal­mol­o­gy.

“I have the priv­i­lege of col­lab­o­rat­ing in the R&D of Lxbio’s bac­te­rio­phage and anti­body prod­ucts, which I believe have the poten­tial to trans­form oph­thal­mol­o­gy prac­tice and improve the qual­i­ty of life for patients world­wide.”

José António Dias, MD

Cor­po­rate pre­sen­ta­tion